0001104659-24-001804 Sample Contracts

Indemnification Agreement
Indemnification Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware

This Indemnification Agreement (this “Agreement”) is made and entered into this [__]th day of [____], 202[ ], by and between ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).

Sample 1Sample 2Sample 3See All (42)
AutoNDA by SimpleDocs
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
Investors’ Rights Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.

Sample 1Sample 2Sample 3See All (18)
RESEARCH COLLABORATION AGREEMENT
Research Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York

This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”

Sample 1Sample 2Sample 3See All (4)
CLINICAL COLLABORATION AGREEMENT
Clinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York

This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Road, ZGC Life Science Park, Changping District, Beijing, China 102206 (“InnoCare”). ArriVent and InnoCare are each referred to herein individually as “Party” and collectively as “Parties”.

Sample 1Sample 2Sample 3
JOINT CLINICAL COLLABORATION AGREEMENT
Joint Clinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations

This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New District, Shanghai, China; and ArriVent BioPharma, Inc. (“ArriVent”), a Delaware corporation, at 18 Campus Blvd. Suite 100, Newport P.A. (each a Party; collectively, Parties.)

Sample 1Sample 2Sample 3
GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd.
Global Technology Transfer and License Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware

This GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”) is effective from the Effective Date by and between:

Sample 1Sample 2Sample 3
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!